SCHEMBL740340

SCHEMBL740340

CNS(=O)(=O)c1cc(Br)cnc1N

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.64
KMT2A Q03164 8/20 0.59
MEN1 O00255 7/20 0.59
ALDH1A1 P00352 1/20 0.58
PLA2G1B P04054 1/20 0.56
ATG4B Q9Y4P1 1/20 0.56
SHMT2 P34897 1/20 0.56
POLB P06746 1/20 0.53
HSD17B10 Q99714 3/20 0.47
KDM4E B2RXH2 2/20 0.47
PIK3C3 Q8NEB9 1/20 0.47
MAPT P10636 2/20 0.46
RAB9A P51151 1/20 0.46
GAA P10253 2/20 0.46
HTT P42858 1/20 0.46
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL858025 0.84 NPC1 (0.61) NPC1KMT2AMEN1ALDH1A1PLA2G1B
SCHEMBL1502699 0.83 NPC1 (0.61) NPC1KMT2AMEN1ALDH1A1PLA2G1B
SCHEMBL858850 0.82 NPC1 (0.59) NPC1KMT2AMEN1ALDH1A1PLA2G1B
SCHEMBL856675 0.82 NPC1 (0.59) NPC1KMT2AMEN1ALDH1A1PLA2G1B
SCHEMBL857446 0.80 NPC1 (0.56) NPC1KMT2AMEN1ALDH1A1PLA2G1B
SCHEMBL22062349 0.79 NPC1 (0.42) NPC1KMT2AMEN1ALDH1A1PLA2G1B
SCHEMBL21494353 0.79 ALPL (0.52) NPC1KMT2AMEN1ALDH1A1PLA2G1B
SCHEMBL856146 0.79 NPC1 (0.56) NPC1KMT2AMEN1ALDH1A1PLA2G1B
SCHEMBL393051 0.78 KMT2A (0.57) NPC1KMT2AMEN1ALDH1A1PLA2G1B
SCHEMBL741358 0.78 HSD17B10 (0.64) NPC1KMT2AMEN1ALDH1A1PLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105916503-B Heteroaryl compounds and uses thereof 米伦纽姆医药公司 2020-04-14 CN disclosed
US-10538533-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2020-01-21 US disclosed
US-20180118762-A1 HETEROARYLS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-03 US disclosed
US-9802960-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-10-31 US disclosed
US-9802960-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-10-31 US disclosed
US-9751854-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-09-05 US disclosed
US-9751854-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-09-05 US disclosed
US-20170073326-A1 HETEROARYLS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-16 US disclosed
US-20170073326-A1 HETEROARYLS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-16 US disclosed
EP-3094325-A1 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2016-11-23 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed
US-20100168100-A1 QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2010-07-01 US disclosed
US-20100168100-A1 QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2010-07-01 US disclosed
US-20100152112-A1 QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2010-06-17 US disclosed
US-20100152112-A1 QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2010-06-17 US disclosed
US-20080300239-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300239-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
WO-2008144463-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 WO disclosed
WO-2008144464-A1 QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152112-A1 QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS JAK3, PI4KA, PIP4K2A NPC1 3641/4885KMT2A 3045/4885MEN1 1896/4885
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA NPC1 1583/4885KMT2A 2645/4885MEN1 3183/4885
US-20100168100-A1 QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS JAK3, PI4KA, PIP4K2A NPC1 3641/4885KMT2A 3045/4885MEN1 1896/4885
US-20180118762-A1 HETEROARYLS AND USES THEREOF VPS35, VPS4B, VPS26B NPC1 33/4885KMT2A 2970/4885MEN1 2561/4885
US-10538533-B2 Heteroaryls and uses thereof VPS35, VPS4B, VPS26B NPC1 33/4885KMT2A 2970/4885MEN1 2561/4885
US-20080300239-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS PIK3CD, PIK3CG, PIK3CB NPC1 3332/4885KMT2A 2511/4885MEN1 2522/4885
US-20170073326-A1 HETEROARYLS AND USES THEREOF VPS35, VPS4B, VPS26B NPC1 33/4885KMT2A 2970/4885MEN1 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.